Add to ORKGBackground: A major impediment to drug diagnosis and therapy of myocardial infarction is the limited access that drugs have to ischemic myocardium, dependent on regional myocardial blood flow. Investigators report that some liposomes concentrate in the experimental myocardial infarction, suggesting that they may be used to transport drugs to a region of ischemia. One of the most promising approaches for increasing liposome circulation time is coating them with polyethyleneglycol (PEG).http://www.sciencedirect.com/science/article/B6WKC-4D0XVDT-3B/1/e8e1e8ec0cf1dcf1546291ba169facf
In this study, PCM and TAT co-modified liposome was developed as a novel drug carrier for myocardium...
AbstractThe development of long-circulating formulations of liposomes (S-liposomes), sterically stab...
After a systemic administration, liposomes are quickly covered by blood proteins leading to the form...
SUMMARY To determine whether liposomes (microscopic phospholipid vesicles) may be useful In deliveri...
Ischemic cardiac disease (ICD) is a cardiovascular disease with high morbidity and mortality. In thi...
ObjectivesThe purpose of this study was to investigate whether liposomal adenosine has stronger card...
AbstractBiodistribution and infarct accumulation of different liposome preparations in rabbits with ...
Item does not contain fulltextAdverse cardiac remodeling after myocardial infarction ultimately caus...
Reperfusion therapy is commonly applied after a myocardial infarction. Reperfusion, however, causes ...
Immunosuppressive agents are used for the treatment of immune-mediated myocarditis; however, the nee...
Liposomes have been considered as almost universal carriers for drugs and diagnostic agents, as they...
Immunosuppressive agents are used for the treatment of immune-mediated myocarditis; however, the nee...
Nowadays, liposomes are the most successful drug delivery systems with a dozen drug products availab...
Strategies used to enhance liposome-mediated drug delivery in vivo include the enhancement of stabil...
AbstractIncorporation of dioleoyl N-(monomethoxy polyethyleneglycol succinyl)phosphotidylethanolamin...
In this study, PCM and TAT co-modified liposome was developed as a novel drug carrier for myocardium...
AbstractThe development of long-circulating formulations of liposomes (S-liposomes), sterically stab...
After a systemic administration, liposomes are quickly covered by blood proteins leading to the form...
SUMMARY To determine whether liposomes (microscopic phospholipid vesicles) may be useful In deliveri...
Ischemic cardiac disease (ICD) is a cardiovascular disease with high morbidity and mortality. In thi...
ObjectivesThe purpose of this study was to investigate whether liposomal adenosine has stronger card...
AbstractBiodistribution and infarct accumulation of different liposome preparations in rabbits with ...
Item does not contain fulltextAdverse cardiac remodeling after myocardial infarction ultimately caus...
Reperfusion therapy is commonly applied after a myocardial infarction. Reperfusion, however, causes ...
Immunosuppressive agents are used for the treatment of immune-mediated myocarditis; however, the nee...
Liposomes have been considered as almost universal carriers for drugs and diagnostic agents, as they...
Immunosuppressive agents are used for the treatment of immune-mediated myocarditis; however, the nee...
Nowadays, liposomes are the most successful drug delivery systems with a dozen drug products availab...
Strategies used to enhance liposome-mediated drug delivery in vivo include the enhancement of stabil...
AbstractIncorporation of dioleoyl N-(monomethoxy polyethyleneglycol succinyl)phosphotidylethanolamin...
In this study, PCM and TAT co-modified liposome was developed as a novel drug carrier for myocardium...
AbstractThe development of long-circulating formulations of liposomes (S-liposomes), sterically stab...
After a systemic administration, liposomes are quickly covered by blood proteins leading to the form...